Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GROINSS-V III
NL-OMON53136Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in vulvar squamous cell carcinoma (VSCC), sponsored by University Medical Center Groningen. Primary endpoint: Groin recurrence rate in the first two years after primary treatment. Started Mar 2021; status: recruiting.
02
Drugs
cisplatin
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON53136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53136.